International Clinical Trial: An open-label, single-center, single-arm Phase IIa study to evaluate the safety and efficacy of Vebreltinib in combination with Third-generation EGFR-TKI in patients with locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122473) titled 'An open-label, single-center, single-arm Phase IIa study to evaluate the safety and efficacy of Vebreltinib in combination with Third-generation EGFR-TKI in patients with locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation' on April 14.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

Condition: EGFR 21L858R-mutated locally advanced or metastatic non-small cell lung cancer

Recruitment Status: Recruiting

Phase: 2

Date of First Enrollment: 2024-10-21

Target Sample Size: EGFR 21L858R mutation:...